Clinical Trial Update: A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing atezolizumab plus adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in operable triple-negative breast cancer; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Doxorubicin (doxorubicin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Triple Negative Breast Cancer | Phase 3 | Status: TERMINATED | Results posted: 2024-08-21